All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution.
作者信息
Grimm Dirk
机构信息
Heidelberg University Hospital, Cluster of Excellence CellNetworks, Department of Infectious Diseases, Virology, Heidelberg, Germany.
出版信息
Mol Ther. 2012 Sep;20(9):1661-1663. doi: 10.1038/mt.2012.173.
Abstract
摘要
相似文献
1
All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution.
Mol Ther. 2012 Sep;20(9):1661-1663. doi: 10.1038/mt.2012.173.
2
Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.
Mol Ther. 2012 Sep;20(9):1724-1736. doi: 10.1038/mt.2012.107. Epub 2012 May 22.
3
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.
Mol Ther. 2012 Sep;20(9):1737-1749. doi: 10.1038/mt.2012.119. Epub 2012 Jun 26.
4
Potential applications of siRNA in hepatitis C virus therapy.
Curr Opin Investig Drugs. 2006 Feb;7(2):142-6.
5
In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.
Sci Rep. 2014 Apr 23;4:4750. doi: 10.1038/srep04750.
6
Galactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo.
Adv Healthc Mater. 2016 Nov;5(22):2931-2941. doi: 10.1002/adhm.201600416. Epub 2016 Oct 24.
7
Opportunities for treating chronic hepatitis B and C virus infection using RNA interference.
J Viral Hepat. 2007 Jul;14(7):447-59. doi: 10.1111/j.1365-2893.2006.00818.x.
8
[Using RNA interference to treat hepatitis virus: hope for future development].
Zhonghua Gan Zang Bing Za Zhi. 2004 Sep;12(9):555.
9
[Current Guidelines for treatment of hepatitis C. The eradication of HCV as a goal].
Pharm Unserer Zeit. 2011 Jan;40(1):52-9. doi: 10.1002/pauz.201100400.
10
Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES).
Colloids Surf B Biointerfaces. 2016 Oct 1;146:808-17. doi: 10.1016/j.colsurfb.2016.07.026. Epub 2016 Jul 12.
引用本文的文献
1
Up-regulation of microRNA-203 in influenza A virus infection inhibits viral replication by targeting DR1.
Sci Rep. 2018 May 1;8(1):6797. doi: 10.1038/s41598-018-25073-9.
2
Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.
Adv Drug Deliv Rev. 2016 Sep 1;104:93-109. doi: 10.1016/j.addr.2015.12.004. Epub 2015 Dec 10.
3
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
Antiviral Res. 2013 Nov;100(2):555-61. doi: 10.1016/j.antiviral.2013.09.020. Epub 2013 Sep 30.
4
Evolution of animal and plant dicers: early parallel duplications and recurrent adaptation of antiviral RNA binding in plants.
Mol Biol Evol. 2013 Mar;30(3):627-41. doi: 10.1093/molbev/mss263. Epub 2012 Nov 22.
本文引用的文献
1
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.
Mol Ther. 2012 Sep;20(9):1737-1749. doi: 10.1038/mt.2012.119. Epub 2012 Jun 26.
2
Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.
Mol Ther. 2012 Sep;20(9):1724-1736. doi: 10.1038/mt.2012.107. Epub 2012 May 22.
3
New targets for antiviral therapy of chronic hepatitis C.
Liver Int. 2012 Feb;32 Suppl 1:9-16. doi: 10.1111/j.1478-3231.2011.02701.x.
4
In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy.
Antimicrob Agents Chemother. 2012 Mar;56(3):1364-75. doi: 10.1128/AAC.05357-11. Epub 2011 Dec 27.
5
The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression.
Silence. 2011 Oct 26;2:8. doi: 10.1186/1758-907X-2-8.
6
Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV.
Virol J. 2011 Jun 10;8:295. doi: 10.1186/1743-422X-8-295.
7
Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster.
Hepatology. 2010 Dec;52(6):1877-87. doi: 10.1002/hep.23908. Epub 2010 Oct 7.
8
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver.
J Clin Invest. 2010 Sep;120(9):3106-19. doi: 10.1172/JCI43565. Epub 2010 Aug 9.
9
Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus.
RNA. 2009 May;15(5):898-910. doi: 10.1261/rna.1268209. Epub 2009 Mar 26.
10
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5868-73. doi: 10.1073/pnas.0801775105. Epub 2008 Apr 8.
Zotero 插件